But, she adds, “we think that we can open up the indications in which the peptide [molecule] could be effective”.
“We have already started some experiments,” Mulller says, which will target a range of diseases including inflammatory, chronic, those related to autoimmunity and those that aren’t - like asthma.
“We have first indication that are extremely promising also in these indications,” she adds.
.#ImmuPharma announces commencement of dosing in first European patients. @PanmureGordon https://t.co/CgtPQK3Dcp pic.twitter.com/8PDPrguZCW— Research Tree (@research_tree) June 8, 2016
@DirectorsTalk interview with Tim McCarthy, Chairman of #immupharma— ImmuPharma (@ImmuPharma) May 6, 2016
for full interview please click on https://t.co/7O2oGqC8Z6
Lupuzor d’ImmuPharma, l’alchimie d’un futur blockbuster : https://t.co/5f167DLUUp $IMM #lupus #lupuzor #ImmuPharma— Alerte Trading **** (@alertetrading) January 3, 2016
#Lupus treatment: #Lupuzor cleared for Phase III trials #ImmuPharma #CNRSNews https://t.co/YqsU4SxIJs pic.twitter.com/7dLfz4OkJ7— CNRS (@CNRS) December 16, 2015